key: cord-0847528-aelpv8s8
authors: Almanza, Gonzalo; Kouznetsova, Valentina; Clark, Alex E.; Olmedillas, Eduardo; Castro, Andrea; Tsigelny, Igor F.; Wu, Yan; Gao, George F.; Saphire, Erica Ollmann; Carlin, Aaron F.; Zanetti, Maurizio
title: Structure-selected RBM immunogens prime polyclonal memory responses that neutralize SARS-CoV-2 variants of concern
date: 2021-10-04
journal: bioRxiv
DOI: 10.1101/2021.10.01.462840
sha: 7516893160a3b1c359887684a8442ab7d63331a4
doc_id: 847528
cord_uid: aelpv8s8

Successful control of the COVID-19 pandemic depends on vaccines that prevent transmission. The full-length Spike protein is highly immunogenic but the majority of antibodies do not target the virus: ACE2 interface. In an effort to concentrate the antibody response to the receptor-binding motif (RBM) we generated a series of conformationally-constrained immunogens by inserting solvent-exposed RBM amino acid residues into hypervariable loops of an immunoglobulin molecule. Priming C57BL/6 mice with plasmid (p)DNA encoding these constructs yielded a rapid memory response to booster immunization with recombinant Spike protein. Immune sera antibodies bound strongly to the purified receptor-binding domain (RBD) and Spike proteins. pDNA primed for a consistent response with antibodies efficient at neutralizing authentic WA1 virus and two variants of concern (VOC), B.1.351 and B.1.617.2. These findings demonstrate that immunogens built on structure selection can focus the response to conserved sites of vulnerability shared between wildtype virus and VOCs and induce neutralizing antibodies across variants.

The current SARS-CoV-2 pandemic has been globally disruptive (Nicola et al, 2020) . 58

Nonpharmaceutical interventions (NPI) have reduced viral transmission but are difficult to 59 (Benton et al, 2020) . A primary antibody response was evident in group 1 and 2 suggesting 156 a more favorable surface exposure and spatial orientation of the FNCY patch and 157 surrounding residues in the immunogenic proteins coded by pDNA1 and pDNA2. 158

The antibody response post-booster immunization was analyzed at an early (day 30) 159 and late (day 45) time point (i.e., 9 and 24 days after booster), to capture the evolution of 160 the memory response. Nine days post-boost antibodies to RBD were markedly increased 161 relative to day 21 both in group 1 and 2. The response was also greater than in group 3 and 162 4. Since group 4 controls for magnitude and speed of the antibody response after booster 163 with intact Spike protein, the data show that pDNA priming accelerated the recall antibody 164 response by the Spike protein. Not surprisingly, sera from group 1 and 2 also had a 165 markedly stronger response to the Spike protein compared to group 3 and 4 (Fig. 2) . 166

Twenty-four days post-boost the responses against the RBD and Spike proteins were 167 considerably stronger than on day 30 and substantially similar among groups (Fig. 2) . 168

Collectively, the three pDNA immunogens differed in their ability to prime a specific B cell 169 response and generate an anamnestic response in a prime-boost regimen. A greater 170 response against the RBM B cell epitope was associated with expression of the RBM epitope 171 in the CDR2 loop of the VH, suggesting context-dependent immunogenicity perhaps owing 172 to better folding and more favorable recognition by B cells relative to expression in CDR3. 173

The B cell epitope selected for these studies is contained in a narrow region of the 174 RBM. To monitor the reactivity of serum antibodies with greater precision we synthesized 175 peptide 475 AGSTPCNGVEGFNCYFPLQSYGFQPT 500 . Reactivity against the RBM peptide 176 occurred after booster immunization with binding profiles on day 9 post-booster mimicking 177 those on RBD and Spike proteins in group 1 and 2, which displayed overall stronger binding 178 relative to group 3 and 4 (Fig. S2A ). Intra-spleen pDNA priming induces predominantly IgM 179 antibodies (Gerloni et al, 1998) , which may account for a weak binding to the RBM peptide 180 at 1:50 dilution, suggesting low antibody concentration in sera, low avidity, or both. 181 Antibody binding increased by day 45 (Fig. S2A) . Thus, priming with pDNA1 and pDNA2 182 generated a pool of memory B cells specific for an RBM epitope comprised within residues 183 475 AGSTPCNGVEGFNCYFPLQSYGFQPT 500 that were expanded during the anamnestic 184 response. 185 Immune sera antibodies cross-compete RBD binding of neutralizing human 186 monoclonal antibodies 187

The RBM amino acids grafted into CDR loops comprise contact residues shown to be targets 188 of potently neutralizing antibodies derived from COVID-19 patients. Among those are 189 antibodies B38 and CC12.1 (Rogers et al., 2020) , which map an 190 overlapping RBM epitope including contact residues Phe -Asn and Tyr of the 486 FNCY 489 191 patch in both cases ( Fig 3A) . 192

We reasoned that the paratope of these two antibodies could be used to determine 193 shared epitope specificity between immune serum polyclonal antibodies and human 194 neutralizing antibodies. To this end, we designed a competitive ELISA assay where the 195 binding of horseradish peroxidase (HRP)-labeled B38 and CC12.1 to the RBD protein was 196 competed by individual immune sera. HRP-labeled B38 and CC12.1 bound RBD with similar 197 characteristics ( Fig. 3B and D) so that both antibodies could be used at the same (~1.5 198 ng/well) effective ~50% binding concentration. Unlabeled antibodies B38 and CC12.1 199 inhibited homologous RBD binding at similar concentration (50% inhibition at ~ 60 200 ng/well) ( Fig. 3B and D, inset) . 201

The majority of immune sera tested individually at a 1:50 dilution inhibited >50% 202 the binding to RBD by both HRP-B38 and HRP-CC12.1. Inhibition in group 2 was overall the 203 strongest (range 25-85% for B38; and 30-84% for CC12.1) (Fig 3C and E) . Surprisingly, 204 group 3 immune sera also inhibited (range 62-80% on B38; and 38-52% on CC12.1). Group 205 4 had overall the weakest inhibitory activity (<30%) with the exception of one mouse. The 206 fact that serum antibodies from immune mice cross-competed the RBD binding of the two 207 human neutralizing antibodies indicates that a component of serum antibodies in the 208 immune serum share the paratope with antibodies B38 and CC12.1. We estimated that the 209 upper limit serum concentration of such antibodies as high as ~12 µg/ml. Collectively, the 210 results show that intra-spleen immunization with pDNA coding for the selected RBM 211 epitope activates, and subsequently facilitates, the expansion of B cell clonotypes producing 212 RBM antibodies found in COVID-19 patients. Oddly, neither HRP-B38 nor HRP-CC12.1 213 bound to 475 AGSTPCNGVEGFNCYFPLQSYGFQPT 500 peptide in ELISA ( Fig. S2B and C) , 214

suggesting perhaps that the synthetic peptide lacks the conformation/structure the 215 paratope of these antibodies needs for binding. Thus, immune sera have a wider spectrum 216 of paratopes than those defined by the two human monoclonal antibodies. In conclusion, we demonstrate that immune mice sera neutralize not only authentic WA1 255 virus but also two VOCs responsible for rapid spreading of infection and disease. 256

We used computer modeling techniques to model the RBM B cell epitope CNGVEGFNCYFP particularly by group 2 sera, was not. Compellingly, this shows that few critical solvent-306 exposed amino acids in the RBM can expand B cells with a paratope specific for the RBM. 307

One may argue that neutralization of the two VOCs by polyclonal antibodies in immune sera 308 is owed to recognition of a discrete epitope within the RBM that is conserved among the 309 study. Collectively, this shows that when this B cell epitope is conformationally-constrained 315 in the CDR2 is not only immunogenic but also captures a spectrum of paratopes efficient at 316 neutralizing across the WA1 virus, and the B.1.351 and B.1.617.2 variants of concern. This 317 stresses the importance of defining immunogenic sites at the structure/function level for 318 efficient precision immunization. 319

Our study has limitations. First, the sample size was deliberately low since the study 320 was designed to identify (a) pDNA with ability to prime RBM-specific B cells that could be 321 re-expanded during a recall response, and (b) yield consistent virus neutralization. In spite 322 of this limitation we managed to identify the immunogen yielding the overall more 323 consistent response. The second is that the dose of Spike protein used in the booster 324 immunization was probably excessive as this protein is highly immunogenic. This may have 325 masked the true potential of the memory response. Future experiments will need to assess 326 memory responses against booster immunization with lower doses of antigen. Finally, 327

although the study was successful in identifying an optimal prime-boost combination The experimental design is illustrated in Fig. 1 . The overall objective of the study was to 381 identify an immunogen able to prime a polyclonal response expandable as a memory 382 response upon boost immunization while enriching for antibodies recognizing a specific 383 site in the RBM ridgeline. 384

The generation of SARS-CoV-2 HexaPro Spike variant D614G and soluble RBD (sRBD) was 386 performed as follows. SARS-CoV-2 HexaPro ectodomain containing residues 14-1208 387 were mixed in Opti-PRO SFM (Gibco) according to the manufacturer's instructions, and added to the cells. One day after the transfection, cells were fed with manufacturer-supplied 404 feed and enhancer as specified in the manufacturer's according to protocol, and cultures 405 were set to 32 ˚C, 5% CO 2 and 115 RPM. One week later, supernatants were clarified by 406 centrifugation, BioLock was added, passaging through a 0.22 µuM sterile filter, and proteins 407 were first purified on an ӒKTA go system (Cytivia) using a 5mL StrepTrap-HP column 408 equilibrated with TBS buffer (25mM Tris pH 7.6, 200mM NaCl, 0.02% NaN 3 3) and eluted 409 using TBS buffer supplemented with 5mM d-dDesthiobiotin (Sigma Aldrich). Proteins were 410 then second purified by size-exclusion-chromatography (SEC) on a Superdex 6 increase 411 10/300 column (Cytivia) in the same TBS buffer. Human monoclonal antibodies B38, 412 CC12.1 and CC6.30 have been described previously (Rogers et al., 2020; Wu et al., 2020) . 413

The RBM peptide 475 AGSTPCNGVEGFNCYFPLQSYGFQPT 500 was synthesized by Synthetic 414

Biomolecules (San Diego) and purified by HPLC (>90% purity). 415

Engineering methods were a modification of those described in (Xiong et al, 1997) . Briefly, 418 the three VH genes matching the descriptions of Model 1-3 as shown in Fig. 1 were 419 synthesized with unique ends for cloning into the ZUC1.1 (9.7 Kb) target vector using the 420 cloning site as shown in Fig. S4 . The ZUC1.1 plasmid lacks Amp resistance gene and SV40 421 sequences, and is optimized for human use. The amino acid sequences of the Variable 422 domain of Model 1-3 are shown in Fig. S1 . pDNAs were prepared from transformed DH5a 423

Escherichia coli according to standard procedures and were analyzed for purity using the 424 following equation: %N=(11.1R-6.32)/(2.16-R) where R=260nm/ 280nm, %N=% of nucleic 425 acid 42 . pDNAs were resuspended in sterile saline solution and stored at -20 °C until use. 426

Twelve-week-old female C57Bl/6 (H-2 b ) were bred at the University of California, San Diego 428 animal facility where they were kept throughout the performance of the experiment. RBD protein (4 µg/ml). Binding was revealed as described above. 454

All work with SARS-CoV-2 was conducted in Biosafety Level-3 conditions at the University 456 of California San Diego following the guidelines approved by the Institutional Biosafety 457

Committee. SARS-CoV-2 isolates WA1(USA-WA1/2020, NR-52281) and B. Computational models utilized the coordinates of rearranged murine VH62 (Sollazzo et al, 499 1989 ). Model predictions have made using SWISS-MODEL, an automated protein structure 500 homology-modelling server and the coordinates of the crystal structure of an antibody: 501 antigen complex (SMTL ID: 5mhe.1) where the antibody is specific for L-Thyroxine, which is 502 also the epitope specificity of monoclonal antibody 62 from which VH62 was originally 503 cloned (Sollazzo et al., 1989) . 

Van der Veken L The COVID-19 vaccines are here: What 555 comes next?

Antibody Immunodominance: The Key to 558 Understanding Influenza Virus Antigenic Drift

A perspective on potential antibody-dependent enhancement of 561 SARS-CoV-2

SARS-CoV-2 neutralizing antibody structures 564 inform therapeutic strategies

Structures of Human Antibodies 567 Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies

Autoantibodies against type I IFNs in patients with life-571 threatening COVID-19

Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion

Sensitivity in Detection of Antibodies to Nucleocapsid and Spike 577 Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Coronavirus 578 Disease

The unsung virtue of thermostability

Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent 582 plasma

A neutralizing human antibody binds to the N-terminal domain of the Spike protein of 585 SARS-CoV-2

Slow Delivery Immunization Enhances HIV 588

Neutralizing Antibody and Germinal Center Responses via Modulation of Immunodominance

Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited 592 antibodies

The antigenic anatomy of SARS-CoV-2 receptor binding domain

Multiple SARS-CoV-2 variants escape 601 neutralization by vaccine-induced humoral immunity

Immunity to Plasmodium falciparum malaria 603 sporozoites by somatic transgene immunization

DNA immunization in relB-deficient mice discloses a role for 605 dendritic cells in IgM-->IgG1 switch in vivo

Personalized Virology Initiative study g

SARS-CoV-2 608 spike E484K mutation reduces antibody neutralisation

Humoral and circulating follicular helper T cell responses in recovered 611 patients with COVID-19

Complex Antigens Drive Permissive Clonal Selection in Germinal Centers

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

Cutler 622 M et al (2021) Neutralizing Activity of BNT162b2-Elicited Serum

Structural basis for neutralization of SARS-CoV-2 and SARS-CoV by a potent therapeutic 626 antibody

Vaccination in Africa -Lessons from the HIV Pandemic

The 630 socio-economic implications of the coronavirus pandemic (COVID-19): A review

immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous 634 recognition by T cells

Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-637 CoV antibody

Correlates of protection induced by vaccination

Longitudinal antibody repertoire in "mild" versus "severe" COVID-19 642 patients reveals immune markers associated with disease severity and resolution

Woehl J 644 et al (2020) Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease 645 in a small animal model

Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351

A human 650 neutralizing antibody targets the receptor-binding site of SARS-CoV-2

Molecular 652 characterization of the VH region of murine autoantibodies from neonatal and adult BALB/c 653 mice

Cellular immune correlates of protection against symptomatic 656 pandemic influenza

Deep Mutational Scanning of SARS-CoV-2 Receptor 659

Binding Domain Reveals Constraints on Folding and ACE2 Binding

Ultrapotent human antibodies protect against SARS-CoV-2 662 challenge via multiple mechanisms

Prevalent, protective, and convergent IgG recognition of SARS-665

CoV-2 non-RBD spike epitopes

Ultrapotent antibodies against diverse and highly transmissible SARS-668 CoV-2 variants

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Escape from neutralizing antibodies by SARS-CoV-2 673 spike protein variants

Serum Neutralizing Activity Elicited by mRNA-1273

A 679 noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its 680 receptor ACE2

Engineering vaccines with heterologous B and T cell 682 epitopes using immunoglobulin genes

IgG-mediated immune suppression in mice is epitope specific 684 except during high epitope density conditions

686 RW et al (2021) Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 687 variants

A highly 689 conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV

Antigenized antibodies

Antigenized antibodied from concept to applications

The Antibodies. Hardwood Academic Publishers

B lymphocytes as antigen-695 presenting cell-based genetic vaccines

Potently neutralizing and protective human antibodies against SARS-CoV-698 2

Autoimmunity to the Lung Protective Phospholipid-Binding Protein Annexin A2 Predicts 701 Mortality Among Hospitalized COVID-19 Patients

Prothrombotic autoantibodies in serum from patients hospitalized with 704 COVID-19

Overview of SARS-CoV-2 epitope selection, protein engineering, and immunization

SARS-CoV-2 Spike protein (yellow) interacting with ACE2 (blue), PDB ID: 6M0J. A zoomed 755 view shows SARS-CoV-2:ACE2 interacting residues. (B) Spike protein RBM

Purple residues indicate ACE2 binding, dots above residues indicate B38 or CC12.1 antibody 757 binding. Immunogens models 1-3 span the putative B cell epitope FNCY

CDR3 (red). (D) Timeline of priming (day 0), and 759 booster shot (day 21)

ELISA binding of immune sera of mice after prime-boost. Binding to RBD (A) 786 and Spike protein (B) of sera at the timepoints indicated. Closed symbols refer to 787 individual mice. Open symbols refer to binding of pre-immune sera. Results are from 788 one experiment representative of three independent runs. Color scheme: red = group 789 1

Polyclonal antibodies in immune sera share paratope specificity with 804 Class 1 human neutralizing antibodies B38 and CC12.1. Immune sera were tested 805 in a cross-competition RBD binding assay by ELISA. (A) Heatmap of neutralizing 806 antibody contact residues (purple) with RBM region (positions 437-508). Black dots 807 indicate ACE2 contact residues. (B) Titration of binding of HRP-B38 to RBD in ELISA. 808 Inset: Slope of inhibition of HRP-B38 binding by unlabeled antibody B38. (C) Binding 809 of HRP-B38 in the presence of 1:50 dilution of individual mouse serum

Inset: Slope of inhibition of HRP-811 CC12.1 binding by unlabeled antibody CC12.1. (E) Binding of HRP-CC12.1 in the 812 presence of 1:50 dilution of individual mouse serum (day 45)

ALI media (StemCell #05021) supplemented with 10μM ROCK inhibitor (Tocris Y-27632). 476Upon reaching confluency, the apical media was removed (airlift) and the basal media 477 replaced with PneumaCult TM ALI media without Y-27632. Subsequent media changes were 478 every 2-3 days thereafter. On Day 14 post-airlift, the apical surfaces were washed with 479 DPBS once per week. Cells were grown in 37°C, 5% CO 2 incubator until four weeks airlifted. 480

After two 30 min incubations with PBS at 37°C, 5% CO 2, virus diluted in PBS was added to 482 apical chambers in 100uL. Virus was removed after 24h and apical washes (150uL PBS with 483 10 min incubation at 37°C, 5% CO 2, ) were taken daily and stored at -80. Titers were 484 determined by fluorescent focus assay on TMPRSS2-Vero cells. 485

Neutralizing antibodies in immune sera were screened through the focus reduction 487 neutralization test (FRNT). Briefly, ~100 focus forming units (ffu) of SARS-CoV-2 were 488 incubated with or without serially diluted antibodies for 1 hour in DMEM with 1% FBS at 37 489 °C before adding to 100% confluent TMPRSS2-Vero cell monolayers in 96 well plates. green -RBM; blue -ACE2 contact residues; B and C: yellow -CDR1; green -CDR2; orange 898 -CDR3; blue -SARS-Cov-2 RBM residues grafted in CDR2; gray -tetanus toxoid epitope; 899 D: pink -ACE2; green -SARS-Cov-2 RBM residues; E: pink -ACE2; blue -SARS-Cov-2 900 RBM residues grafted in CDR2. 901 902 903